Thrombosis
Aspirin unneeded with anticoagulation/clopidogrel after MI, PCI in AF
9 COMMENT S - Jun 6, 2013 17:00 EDT
A large national cohort study somewhat confirms what the WOEST trial suggested: that an oral anticoagulant plus one antiplatelet is sufficient in patients with multiple indications for antithrombotic therapy.

Copenhagen, Denmark - The addition of one antiplatelet agent to oral anticoagulation is sufficient in patients with atrial fibrillation (AF) who experience an MI or PCI, and the antiplatelet agent probably should be clopidogrel instead of aspirin, concluded a study of >12 000 patients from nationwide registries in Denmark [1].

Despite the common recommendation for triple antithrombotic therapy in patients with multiple indications for antithrombotic therapy, which would have added aspirin into the mix, "Our data suggest that triple-therapy-management regimens might be replaced with oral anticoagulation and clopidogrel without any additional risk of recurrent thrombotic events and a lower risk of bleeding," according to the authors, led by Dr Morten Lamberts (Copenhagen University Hospital Gentofte, Hellerup, Denmark).
Read full article »

MediaPulse
Yaz, Yasmin BCPs linked to 23 deaths in Canada
Jun 13, 2013 16:50 EDT

Arrhythmia/EP
Severe sleep apnea may almost double risk of sudden cardiac death
Jun 12, 2013 17:00 EDT

Arrhythmia/EP
AF linked to earlier, more rapid cognitive decline
Jun 7, 2013 14:00 EDT

Lipid/Metabolic
Rosiglitazone restrictions should be eased, says FDA advisory panel
Jun 6, 2013 21:45 EDT

Lipid/Metabolic
FDA says again: Rosiglitazone does not up CV risk 
Jun 6, 2013 12:15 EDT

Acute Coronary Syndromes
AMI, sudden death tracked with seismic activity during East Japan quake
Jun 5, 2013 08:30 EDT

Editorial programs
Debate and dialogue between top cardiovascular specialists, produced by
theheart.org's editorial team
View all »
EuroPCR 2013 research highlights: A slideshow presentation
EuroPCR 2013 research highlights: A slideshow presentation
Jun 5, 2013 15:05 EDT
Life and times of leading cardiologists. Guest: Richard Schatz
Life and times of leading cardiologists. Guest: Richard Schatz
Jun 3, 2013 09:45 EDT
Healthcare reform and cardiology: An even-keeled update
Healthcare reform and cardiology: An even-keeled update
May 2, 2013 08:45 EDT
View all »Collections
heartwire collections groups our most compelling cardiology news coverage and editorial content by popular themes. Find everything on a single topic, in one place, with one click.
Antiplatelet up-and-comers
The quest for ever-more effective drugs to decrease platelet aggregation and reduce the...
Erectile dysfunction and CHD
Years ago, Viagra made the unexpected transition from hypertension and angina drug...
Aspirin and primary prevention
Long considered an essential agent for primary cardiovascular disease prevention...
Dabigatran: A chronology
The presentation of the RE-LY results at the 2009 ESC meeting, showing that dabigatran...
Drugs, money, and glory: Is cancer beating cardiovascular disease?
Heart disease still tops the charts as the number-one killer in most developed...
Related themes
View all »
Other programs
CV & GI Risk
The satellite programs of the CV & GI Risk section are accredited by Medscape. The steering committee members are active in overseeing the development and direction of this educational series.
The Heart of a Woman
Resource Center (view all)